Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Oncogene. 2015 Apr 13;35(4):459–467. doi: 10.1038/onc.2015.97

Fig. 3. The B-Raf inhibitor PLX4032 decreases cell surface DR5 levels (A and B) and suppresses DR5 transcription (C and D).

Fig. 3

A and B, A375 (A) or LOXIMVI (B) cells were exposed to 5 μM PL4032 (PLX) for 16 h and then harvested for detection of cell surface DR5 levels with flow cytometry. The data are means ± SDs of triplicate determinations. Ab, antibody. C, BCPAP cells were treated with the indicated concentrations of PLX4032 for 12 h and then harvested for extraction of cellular total RNA and subsequent RT-PCR to detection of DR5. D, 293T cells were co-transfected with DR5 reporter construct and B-Raf (V600E) expression plasmid for 23 h and then exposed to the indicated concentrations of PLX4032 for additional 10 h before the cells were harvested for luciferase assay. The data are means ± SDs of triplicate determinations